PT-141 side effects most often include nausea, flushing, headache, and injection-site reactions. In the pooled RECONNECT trials, nausea affected 40.0% of bremelanotide participants, flushing 20.3%, headache 11.3%, and injection-site reactions 5.4%. The less common concerns that change screening are a temporary rise in blood pressure and focal skin darkening. Evidence in men is older and thinner, so those modern percentages should not be presented as male-specific rates.
PT-141 and bremelanotide name the same peptide. The clearest safety numbers come from the branded bremelanotide development program in premenopausal women, not from every compounded formulation, route, or population.
PT-141 side effects at a glance
The two phase 3 RECONNECT trials enrolled 1,267 women with acquired, generalized hypoactive sexual desire disorder; 1,247 were included in the safety population. The integrated adverse-event analysis reported the following rates (Kingsberg et al., Obstetrics & Gynecology, 2019; Clayton et al., Journal of Women's Health, 2022):
| Adverse event | Bremelanotide | Placebo |
|---|---|---|
| Nausea | 40.0% | 1.3% |
| Flushing | 20.3% | 1.3% |
| Headache | 11.3% | 1.9% |
| Injection-site reactions | 5.4% | 0.5% |
Most events in RECONNECT were mild or moderate. Nausea still mattered: it was the leading reason participants stopped treatment. Its median onset was 30 minutes after administration and its median duration was 2.4 hours. About 8.1% discontinued because of nausea, while 3.5% reported vomiting at the same time.
These are trial averages, not a forecast for one person. The participants were mostly white women, the mean age was 39, and people with uncontrolled hypertension or recent cardiovascular problems were excluded. That makes the table useful and also sets its limits. The receptor biology is covered separately in how PT-141 works.
Why the blood-pressure effect changes screening
Bremelanotide can briefly raise blood pressure while lowering heart rate. RECONNECT reported placebo-adjusted mean increases of about 3 mm Hg systolic and 2 mm Hg diastolic. The changes appeared within two hours and returned to baseline within 8–10 hours.
A separate randomized study used ambulatory monitors in 397 premenopausal women with normal or controlled blood pressure. At the studied regimen, systolic increases versus placebo were about 3.1–3.2 mm Hg; peak increases typically lasted less than 15 minutes, and heart rate fell by about 4.6–4.7 beats per minute (White et al., Journal of Hypertension, 2017). An average that looks small does not erase individual cardiovascular risk.
The branded label lists uncontrolled hypertension and known cardiovascular disease as contraindications. A 2022 clinical review summarizes the same boundary and connects it to the transient pressure rise (Edinoff et al., Neurology International, 2022). Controlled hypertension is a different clinical question, but it still belongs in prescriber review rather than self-screening.
PT-141 side effects in men: what the trials show
There is no equally large, modern adverse-event dataset for men. A 2004 double-blind study evaluated intranasal PT-141 in healthy men and men with mild-to-moderate erectile dysfunction. Flushing and nausea were the most common adverse events. The investigators reported no clinically significant changes in vital signs, laboratory tests, electrocardiograms, or physical examinations (Diamond et al., International Journal of Impotence Research, 2004). That was an early, short study of a nasal formulation; it cannot establish the risk profile of a compounded injection used over time.
A 2008 randomized study enrolled 342 men whose erectile dysfunction had not responded to sildenafil. Its abstract reported more drug-related adverse effects with intranasal bremelanotide than with placebo but did not give a useful event-by-event breakdown (Safarinejad and Hosseini, The Journal of Urology, 2008). The journal issued an expression of concern in 2023, so that paper deserves less evidentiary weight.
The practical answer to “is PT-141 safe for men?” is therefore conditional. Men appeared to experience the same prominent nausea-and-flushing pattern in early studies, but precise modern rates are unavailable. The RECONNECT percentages belong to women in those trials, not to men by extension.
PT-141 also is not interchangeable with kisspeptin. They are different compounds with different evidence and safety questions, so RECONNECT rates cannot be transferred to kisspeptin as though it were a substitute.
Skin darkening is tied to frequent exposure
Focal hyperpigmentation means darkening in specific areas rather than an even tan. Reports have involved the face, gums, and breasts, and the change may not fully resolve after the medication stops.
Frequency is the important signal. Across the bremelanotide clinical program, focal hyperpigmentation was rare with label-consistent use, but it occurred in more than one-third of participants exposed on as many as 16 consecutive days (Clayton et al., Journal of Women's Health, 2022). This is why a new dark patch belongs in a clinical conversation, especially when exposure has been frequent. The separate PT-141 dosage guide owns schedule and frequency decisions; this side-effects review does not provide a protocol.
Product and route are part of the risk discussion
Promise's PT-141 is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The branded Vyleesi indication covers acquired, generalized hypoactive sexual desire disorder in premenopausal women; it does not extend to men or general sexual-performance use (Clayton et al., Journal of Women's Health, 2022).
A compounded prescription is not the identical product studied in RECONNECT. Formulation, handling, route, and individual history all affect how directly trial results apply. Readers comparing routes can use the dedicated PT-141 nasal spray review, which owns that route-specific evidence.
Regulatory status is not a marketing gate: a licensed provider reviews every Promise request and may still prescribe a compounded formulation when appropriate, but not everyone qualifies; that decision is between the patient and the doctor.
What a careful review should catch
The safety conversation should include blood-pressure control, known heart or blood-vessel disease, prior pigment changes, pregnancy status, and every current medication. Bremelanotide can delay gastric emptying, and the clinical program found reduced plasma exposure to oral naltrexone and indomethacin. That makes the medication list part of the risk assessment, not paperwork.
Chest pain, fainting, symptoms of a severe allergic reaction, or a severe headache with neurologic symptoms warrant urgent medical evaluation. Less dramatic nausea, flushing, headache, or an injection-site reaction still matters when it is intense, persistent, or changing with repeated exposure. Side effects are not just a list to tolerate; they are information a prescriber uses to decide whether the plan remains appropriate.